Arcus Biosciences Inc (RCUS)

Interest coverage

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	-340,000	-323,000	-313,000	-299,000	-280,000	75,019	66,883	59,747	54,000	-278,796	-199,108	-168,347	-124,000	-89,750	-114,551	-98,336	-88,709	-84,666	-73,562	-60,301
Interest expense (ttm)	US$ in thousands	4,000	3,000	2,535	3,046	2,437	1,697	1,162	651	260	0	0	0	0	0	0	0	0	4,922	4,922	4,922
Interest coverage		-85.00	-107.67	-123.47	-98.16	-114.90	44.21	57.56	91.78	207.69	—	—	—	—	—	—	—	—	-17.20	-14.95	-12.25

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $-340,000K ÷ $4,000K
= -85.00

Based on the data provided, it appears that the interest coverage ratio for Arcus Biosciences Inc is not available or has not been reported for any of the quarters listed. The interest coverage ratio is a measure of a company's ability to meet its interest obligations on outstanding debt.

Given the absence of data for the interest coverage ratio, it is challenging to assess the company's ability to cover its interest expenses using its operating income. Regular monitoring and analysis of this ratio, when available, would provide valuable insights into the financial health and risk profile of Arcus Biosciences Inc in terms of its debt obligations. Additional financial information or disclosures may be necessary to further evaluate the company's financial performance and leverage position.